Dr. Matthew Weir, MD
Claim this profileVictoria Hospital
Area of expertise
Kidney Failure
Matthew Weir, MD has run 1 trial for Kidney Failure.
Antibody Mediated Rejection
Matthew Weir, MD has run 1 trial for Antibody Mediated Rejection. Some of their research focus areas include:
Affiliated Hospitals
Victoria Hospital
University Of Maryland
Clinical Trials Matthew Weir, MD is currently running
Phosphate Level Management
for Kidney Failure
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high levels, lowering blood phosphate levels would reduce death or major events due to heart disease, improve physical health, and be cost-effective.
Recruiting
1 award
N/A
4 criteria
Patient-centered Care
for Acute Kidney Injury
The COPE-AKI study is a randomized, pragmatic, parallel-arm trial comparing a multimodal intervention to usual care on hospital-free days through 90 days of study follow up. The primary study hypothesis is that patients randomized to the intervention will have increased odds of more hospital-free days through 90 days (primary clinical) compared to those randomized to usual care. Key secondary hypotheses will investigate the impact of the intervention on rates of major adverse kidney events, rates of recurrent AKI, and changes in patient-reported outcomes. Participants (N=2145) will be allocated 1:1 to the intervention or usual care using a web-based system to maintain allocation concealment using stratified randomization with randomly permuted blocks. Randomization will be stratified by clinical site.
Recruiting
1 award
N/A
2 criteria
More about Matthew Weir, MD
Clinical Trial Related
6 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Matthew Weir, MD has experience with
- Placebo Oral Tablet
- Spironolactone
- Clazakizumab
- Multimodal Intervention
- Intensive Phosphate Target
- Liberal Phosphate Target
Breakdown of trials Matthew Weir, MD has run
Kidney Failure
Antibody Mediated Rejection
Acute Kidney Injury
Renal Disease
Chronic Renal Failure
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Weir, MD specialize in?
Matthew Weir, MD focuses on Kidney Failure and Antibody Mediated Rejection. In particular, much of their work with Kidney Failure has involved treating patients, or patients who are undergoing treatment.
Is Matthew Weir, MD currently recruiting for clinical trials?
Yes, Matthew Weir, MD is currently recruiting for 2 clinical trials in London Ontario. If you're interested in participating, you should apply.
Are there any treatments that Matthew Weir, MD has studied deeply?
Yes, Matthew Weir, MD has studied treatments such as Placebo Oral Tablet, Spironolactone, Clazakizumab.
What is the best way to schedule an appointment with Matthew Weir, MD?
Apply for one of the trials that Matthew Weir, MD is conducting.
What is the office address of Matthew Weir, MD?
The office of Matthew Weir, MD is located at: Victoria Hospital, London, Ontario N6A 5W9 Canada. This is the address for their practice at the Victoria Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.